MHRA Papers - Part 19
Bias and the cracks in the narrative
SUMMARY: signals continue to be ignored while immunity wanes rapidly
After the great interest shown by the UK Parliament, our readers, and the MHRA's enablers, we continue reviewing the minutes of the 18 March 2021 meeting of the MHRA’s Commission On Human Medicines (CHM) COVID-19 Vaccines Benefit Risk Expert Working Group. Oops…. the Minutes have been withdrawn in the interests of transparency, silly us. Never mind; here is the PDF.
This session was first focused on the interim results of the VIVALDI study. VIVALDI was a well-reported prospective cohort study carried out in England's 331 nursing homes (residents and carers) between 2020 and 2021. The study aimed to investigate the long-term duration of protection against symptoms and complications of the Oxford AstraZeneca and PfizerBionTech vaccines. Along the way, the authors also report estimates of the effectiveness of both vaccines, which must be handled with caution.
The study concluded that the duration of protection was sim…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.